Skip to content
Politically.com Search all
Menu

HR 843 119th Congress

Prompt Approval of Safe Generic Drugs Act

To amend the Federal Food, Drug, and Cosmetic Act to provide for the prompt approval of drugs when safety information is added to labeling, and for other purposes.

Official Title as Introduced Congress.gov

Introduced Jan 31, 2025 Latest action Jan 31, 2025 Sponsor: Rep. Barragán, Nanette Diaz [D-CA-44] Health
Open official Congress.gov record
Source: Congress.govUpdated 2026-09-17 20:08:34 UTC.

Source-linked procedural record

Bill journey

5 dated records

This is a chronology, not a progress score. Politically.com does not classify stages or infer what comes next. Records sharing a date are grouped because not every source field supplies a time.

Congress.gov Recently refreshed U.S. Senate XML Recently refreshed
Introduction 1 One supplied introduction date.
Official actions 3 3 dated action records.
Committees 1 1 undated relationship.
Amendments 0 No record is cached.
Text versions 1 1 dated, 0 without a supplied date.
House roll calls 0 No exact legislation-key match in the House-vote cache.
Senate roll calls 0 No exact document-key match in the Senate-vote cache.
Related measures 0 No related-measure relationship is cached.
Linked law 0 No linked law record is cached; this does not predict outcome.
  1. Official action Congress.gov

    Referred to the House Committee on Energy and Commerce.

    IntroReferral · House floor actions · Code H11100

    Open bill record

    Official action Congress.gov

    Introduced in House

    IntroReferral · Library of Congress · Code Intro-H

    Open bill record

    Official action Congress.gov

    Introduced in House

    IntroReferral · Library of Congress · Code 1000

    Open bill record

    Text version Congress.gov

    Introduced in House

    A dated text-version record is available.

    Open text record
View the complete bill journey as an accessible table
Every dated cached record linked to HR 843. Same-date row order does not assert procedural sequence.
Date and timeRecordOfficial detailSource
IntroductionIntroduced Introduced in the House. Congress.gov
Official actionReferred to the House Committee on Energy and Commerce. No additional detail supplied.IntroReferral · House floor actions · Code H11100 Congress.gov
Official actionIntroduced in House No additional detail supplied.IntroReferral · Library of Congress · Code Intro-H Congress.gov
Official actionIntroduced in House No additional detail supplied.IntroReferral · Library of Congress · Code 1000 Congress.gov
Text versionIntroduced in House A dated text-version record is available. Congress.gov

House roll calls join only on matching Congress, legislation type, and number. Senate roll calls join only on matching source-supplied document type and number, not question text. Committee and related-measure relationships have no date in their relationship records and therefore are counted above but never placed on the chronology.

Congressional Research Service

CRS summary

Introduced in House Jan 31, 2025

Prompt Approval of Safe Generic Drugs ActThis bill authorizes the Food and Drug Administration (FDA) to approve certain applications to market a generic drug despite the omission of certain safety information from the generic drug's labeling.Specifically, the FDA may not deem an abbreviated application for approval of a generic drug ineligible for approval solely because the drug's labeling omits safety information that is protected under another drug's patent or exclusivity protections. Similarly, a drug that is approved under this bill may not be considered mislabeled for lacking such safety information.Generally, an abbreviated application, for the purposes of this bill, is one that (1) uses required information from studies not conducted by the applicant; or (2) seeks approval of a drug that is, for drug approval purposes, a duplicate of an already-approved drug (i.e., a generic drug). Currently, the labeling for such a generic drug must generally be identical to that of the already-approved drug. This bill provides an exception to that requirement under the specified circumstances. For any drug approved under this bill, the FDA must require the drug's labeling to include any safety information that is necessary to assure safe use.

Official documents

Text versions